A Phase 3 Study to Evaluate Eptinezumab for the Preventive Treatment of Chronic Migraine: Results of the PROMISE-2 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy–2) Trial

Richard B. Lipton,[1] Peter J. Goadsby,[2] Julia Azimova,[3] Messoud Ashina,[4] Egilius L.H. Spierings,[5] Paul Winner,[6] Barbara Schaeffler,[7] David Biondi,[7] Suman Bhattacharya,[7] Jeff Smith,[8] Roger Cady[7]

Poster # PFO2

Eptinezumab (ALD403) is an IgG1 anti-CGRP monoclonal antibody administered quarterly by iv infusion, allowing for 100% bioavailability



PROMISE 2: Eptinezumab Phase 3 Chronic Migraine Study Design

N=1072



[1]Montefiore Headache Center, Albert Einstein College of Medicine, Bronx, NY; [2]NIHR and Wellcome Trust King's Clinical Research Facility, King's College London, UK; [3]University Headache Clinic, Moscow, Russia; [4]Faculty of Health and Medical Sciences, University of Copenhagen, Denmark; [5]MedVadis Research, Watertown, MA; [6]Premiere Research Institute, Palm Beach Headache Center, West Palm Beach, FL; [7]Alder BioPharmaceuticals, Inc., Bothell, WA; [8]Alder BioPharmaceuticals Ltd, Dublin, Republic of Ireland

Eptinezumab Significantly Reduced Mean MMD Weeks 1–12: Primary Endpoint

Poster # PFO2



- Eptinezumab 100 and 300 mg significantly decreased mean MMD from baseline vs placebo over Weeks 1–12 after the first infusion

MMD, monthly migraine days.

Eptinezumab Subjects Achieved High Rates of ≥50% and ≥75% Migraine Response: Key Secondary Endpoints

Poster # PFO2

Migraine Responder Rates With Eptinezumab

Placebo (n=366) Eptinezumab 100 mg (n=356) Eptinezumab 300 mg (n=350)

Weeks 1–12



Weeks 1–4



*p <0.0001 vs placebo; Migraine responder rates, % of subjects with prespecified reduction from baseline in MMD.

Day 1 Reduction From Baseline in Percentages of Subjects With a Migraine Maintained, on Average, Through 28 Days*

Poster # PFO2



*Day 1 % of subjects with a migraine in eptinezumab vs placebo groups **(p<0.0001 for both doses)** and daily % of subjects with a migraine averaged weekly for Days 1–28 in eptinezumab vs placebo groups **(p<0.0001 for both doses)**

Conclusions

- Eptinezumab subjects showed significant reductions in monthly migraine activity across primary and all key secondary endpoints
- Subjects treated with eptinezumab 300 mg experienced significantly fewer days with migraine
  - >33% of subjects achieved a ≥75% reduction in MMD
  - >61% of subjects achieved a ≥50% reduction in MMD
- The percentage of subjects with a migraine on Day 1 postinfusion dropped by ≥50% compared with baseline and reductions were sustained, on average, through Day 28
- For initial presentation of the data for 2 quarterly infusions of eptinezumab, please stop by Poster PF110LB